Bremnes RM - Search Results

1

High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer.

Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. Bremnes RM, et al. J Clin Oncol. 2002 May 15;20(10):2417-28. doi: 10.1200/JCO.2002.08.159. J Clin Oncol. 2002. PMID: 12011119

2

The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis.

Bremnes RM, Veve R, Hirsch FR, Franklin WA. Bremnes RM, et al. Lung Cancer. 2002 May;36(2):115-24. doi: 10.1016/s0169-5002(01)00471-8. Lung Cancer. 2002. PMID: 11955645 Review.

3

Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.

Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA. Sugita M, et al. Cancer Res. 2002 Jul 15;62(14):3971-9. Cancer Res. 2002. PMID: 12124329

4

WNT7a induces E-cadherin in lung cancer cells.

Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremnes R, Franklin W, Drabkin HA. Ohira T, et al. Among authors: bremnes r. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10429-34. doi: 10.1073/pnas.1734137100. Epub 2003 Aug 22. Proc Natl Acad Sci U S A. 2003. PMID: 12937339 Free PMC article.

5

gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth.

Winn RA, Bremnes RM, Bemis L, Franklin WA, Miller YE, Cool C, Heasley LE. Winn RA, et al. Among authors: bremnes rm. Oncogene. 2002 Oct 24;21(49):7497-506. doi: 10.1038/sj.onc.1205963. Oncogene. 2002. PMID: 12386812

6

[Lung cancer screening--what now?].

Bremnes RM, Hirsch FR. Bremnes RM, et al. Tidsskr Nor Laegeforen. 2001 May 20;121(13):1600-4. Tidsskr Nor Laegeforen. 2001. PMID: 11446046 Review. Norwegian.

7

Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer.

Bremnes RM, Sundstrøm S, Vilsvik J, Aasebø U; Norwegian Lung Cancer Study Group. Bremnes RM, et al. J Clin Oncol. 2001 Aug 1;19(15):3532-8. doi: 10.1200/JCO.2001.19.15.3532. J Clin Oncol. 2001. PMID: 11481360 Clinical Trial.

8

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.

Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. Among authors: bremnes rm. J Clin Oncol. 2002 Dec 15;20(24):4665-72. doi: 10.1200/JCO.2002.12.111. J Clin Oncol. 2002. PMID: 12488411 Clinical Trial.

9

The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.

Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT. Bremnes RM, et al. J Thorac Oncol. 2011 Jan;6(1):209-17. doi: 10.1097/JTO.0b013e3181f8a1bd. J Thorac Oncol. 2011. PMID: 21107292 Free article. Review.

10

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up.

Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S; Norweigian Lung Cancer Study Group. Bremnes RM, et al. Lung Cancer. 2003 Mar;39(3):303-13. doi: 10.1016/s0169-5002(02)00508-1. Lung Cancer. 2003. PMID: 12609569 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

223 results

Search Page